Sign in

    Alexandre Bouilloux • Barclays

    Alexandre Bouilloux is a Vice President and Equity Research Analyst at Barclays, specializing in equity research coverage across financial institutions and select sectors. He covers multiple listed companies, having delivered analytical insight at Barclays following prior roles at Brookside Research, Mizuho, and Credit Agricole CIB. Bouilloux began his analyst career in 2013 as an Associate at Credit Agricole Securities, later advancing through Brookside Research (2016-2017) and Mizuho before joining Barclays, where he now leads sector-focused research teams. He holds professional credentials consistent with senior equity research analysts at major investment banks, and is recognized for his robust analytical contributions and research depth.

    Alexandre Bouilloux's questions to Adaptimmune Therapeutics PLC (ADAP) leadership

    Alexandre Bouilloux's questions to Adaptimmune Therapeutics PLC (ADAP) leadership • Q1 2025

    Question

    Alexandre Bouilloux from Barclays asked for the drop-off rate between patient apheresis and infusion, inquired about any planned manufacturing maintenance shutdowns, and questioned if any price increases were planned for 2025.

    Answer

    CEO Adrian Rawcliffe confirmed the conversion rate from apheresis to infusion has been 100% so far and stated no price increases have been announced. John Lunger, Head of the Manufacturing Group, added that no significant plant shutdowns are planned for the year, as maintenance is conducted on a rolling basis without impacting capacity.

    Ask Fintool Equity Research AI

    Alexandre Bouilloux's questions to Adaptimmune Therapeutics PLC (ADAP) leadership • Q2 2024

    Question

    Alexandre Bouilloux, on for Peter Lawson, asked about the potential for an interim analysis in the SURPASS-3 study, including its timing and any gating factors.

    Answer

    Executive Elliot Norry confirmed that interim analyses are built into the trial design, with the first occurring after 13 patients are dosed in each arm. However, he stressed that the company will not disclose clinical data from this analysis to avoid biasing the potentially registration-enabling study. CEO Adrian Rawcliffe added that full enrollment is expected next year.

    Ask Fintool Equity Research AI